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ABSTRACT
Endothelial barrier dysfunction is a hallmark of many severe
pathologies, including sepsis or atherosclerosis. The cardio-
vascular hormone atrial natriuretic peptide (ANP) has increas-
ingly been suggested to counteract endothelial leakage. Sur-
prisingly, the precise in vivo relevance of these observations
has never been evaluated. Thus, we aimed to clarify this issue
and, moreover, to identify the permeability-controlling subcel-
lular systems that are targeted by ANP. Histamine was used as
important pro-inflammatory, permeability-increasing stimulus.
Measurements of fluorescein isothiocyanate (FITC)-dextran ex-
travasation from venules of the mouse cremaster muscle and
rat hematocrit values were performed to judge changes of
endothelial permeability in vivo. It is noteworthy that ANP
strongly reduced the histamine-evoked endothelial barrier dys-
function in vivo. In vitro, ANP blocked the breakdown of trans-
endothelial electrical resistance (TEER) induced by histamine.
Moreover, as judged by immunocytochemistry and Western
blot analysis, ANP inhibited changes of vascular endothelial
(VE)-cadherin, -catenin, and p120ctn morphology; VE-cad-
herin and myosin light chain 2 (MLC2) phosphorylation; and
F-actin stress fiber formation. These changes seem to be pre-
dominantly mediated by the natriuretic peptide receptor
(NPR)-A, but not by NPR-C. In summary, we revealed ANP as
a potent endothelial barrier protecting agent in vivo and iden-
tified adherens junctions and the contractile apparatus as sub-
cellular systems targeted by ANP. Thus, our study highlights
ANP as an interesting pharmacological compound opening
new therapeutic options for preventing endothelial leakage.
The endothelium crucially participates in the regulation of
important physiological functions, such as blood pressure,
coagulation, or host defense, and it represents a barrier that
controls the passage of cells, macromolecules, and fluid be-
tween the blood and the adjacent tissue interstitium. Beyond
its physiological role, the endothelium is also involved in
pathological conditions: endothelial barrier dysfunction is a
hallmark of inflammatory processes and still poses an impor-
tant therapeutical challenge, because a causal pharmacolog-
ical treatment remains widely lacking.
Endothelial barrier function is mainly governed by the
balance between interendothelial cell adhesion and retrac-
tion. Adherens junctions (AJs) are important subcellular
structures responsible for endothelial cell-cell attachment,
and they represent multiprotein complexes that consist of
vascular endothelial (VE)-cadherin, -catenin, and p120ctn.
Under inflammatory conditions, VE-cadherin junctions dis-
assemble, thus facilitating paracellular passage, and show
an increased tyrosine phosphorylation. Endothelial cell re-
traction is caused by the activation of the contractile machin-
ery [i.e., the interaction between actin and myosin, which is
controlled by phosphorylation of the myosin light chain
(MLC)]. These two regulatory systems could be targets of a
successful therapeutic principle.
Article, publication date, and citation information can be found at
http://molpharm.aspetjournals.org.
doi:10.1124/mol.108.045773.
□S The online version of this article (available at http://molpharm.
aspetjournals.org) contains supplemental material.
ABBREVIATIONS: AJ, adherens junction; VE, vascular endothelial; MLC, myosin light chain; ANP, atrial natriuretic peptide; NPR, natriuretic
peptide receptor; HUVEC, human umbilical vein endothelial cell; TEER, transendothelial electrical resistance; TNF-, tumor necrosis factor-;
FITC, fluorescein isothiocyanate; VEGF, vascular endothelial growth factor; cANF, c-atrial natriuretic factor.
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The cardiovascular hormone atrial natriuretic peptide
(ANP) is secreted by the cardiac atria as response to an
increased plasma volume. In general, ANP binds to the guan-
ylate cyclase-coupled natriuretic peptide receptor (NPR)-A
and NPR-C, which lacks guanylate cyclase function. ANP
exerts a hypotensive effect by its natriuretic, diuretic, and
vasodilating action. The role of ANP as an important regu-
lator of the cardiovascular system is highlighted by the fact
that ANP [carperitide (HANP)] has been approved as drug
for the treatment of acute heart failure in Japan. However,
ANP has been recognized to possess important additional
functions beyond blood pressure regulation: ANP is ex-
pressed by macrophages and is able to influence these im-
mune cells by attenuating their inflammatory response (Ki-
emer and Vollmar, 2001). Most importantly, ANP exerts
anti-inflammatory properties in the endothelium (Kiemer et
al., 2005). Thus, we posed the working hypothesis that ANP
could open new therapeutical options for protecting against
endothelial barrier dysfunction. In fact, some evidence is
given from in vitro and ex vivo experiments that ANP influ-
ences an inflammation-increased permeability (Inomata et
al., 1987; Lofton et al., 1991; Kiemer et al., 2002a). However,
data precisely demonstrating a beneficial effect of adminis-
tered ANP on inflammation-induced endothelial barrier dys-
function in vivo are lacking. Moreover, data concerning the
effect of ANP on subcellular systems that control permeabil-
ity are missing.
Therefore, the aims of the study were 1) to examine the in
vivo potential of ANP as pharmacological agent counteract-
ing endothelial leakage and 2) to investigate the influence of
ANP on key regulators of endothelial permeability [i.e., the
endothelial cell adhesion (VE-cadherin) and contraction sys-
tem (MLC)].
Materials and Methods
Measurement of Vascular Permeability in the Mouse Cre-
master Muscle in Vivo. Male C57BL/6NCrl mice (Charles River
Laboratories, Sulzfeld, Germany) weighing 23 to 25 g were used. All
experiments were performed according to the German legislation for
the protection of animals. Surgery was performed as described by
Baez (1973). Vascular permeability was analyzed according to
Hatekeyama et al. (2006). In brief, mice were anesthetized i.p. using
a ketamine (Pfizer, Karlsruhe, Germany)/xylazine (Bayer, Le-
verkusen, Germany) mixture. Fluorescein isothiocyanate-dextran
(150 kDa; Sigma-Aldrich, Taufkirchen, Germany), Ringer solution
(control), and ANP (bolus sufficient to reach 200 nM plasma concen-
tration; AnaSpec/MoBiTec, Go¨ttingen, Germany) were applied into
the left femoral artery. Twenty minutes after ANP application, the
cremaster was superfused with histamine (30 M; Sigma-Aldrich)
for 10 min. Dexamethasone 21-phosphate (disodium salt; Sigma-
Aldrich) was administered i.p. (10 mg/kg of body weight) 2 h before
histamine. Postcapillary venules with diameters of 18 to 30 m were
analyzed. Ten regions of interests (50  50 m2) in the interstitial
tissue (approximately 50 m distant from the venule) were randomly
selected. Intravital microscopic images were recorded with an
IMAGO charge-coupled device camera (TILL Photonics, Gra¨felfing,
Germany) and subjected to digital image analysis (TILLvisION 4.0;
TILL Photonics).
Measurement of Rat Hematocrit. Male Sprague-Dawley rats
(Charles River Laboratories) weighing 190 to 240 g were used. All
experiments were performed according to the German legislation for
the protection of animals. Rats were anesthetized i.p. using a fent-
anyl (Jansen-Cilag, Neuss, Germany)/midazolam (Ratiopharm, Ulm,
Germany) mixture, and anesthesia was maintained by 1.5% isoflu-
rane (Abbott, Wiesbaden, Germany). Rats were pretreated for 15 min
with ANP (bolus sufficient to reach 200 nM plasma concentration) or
PBS, followed by histamine (bolus sufficient to reach 1 M plasma
concentration). Reagents were applied into the jugular vein. Thirty
minutes after administration of histamine, blood samples were col-
lected via a jugular artery catheter, and hematocrit was determined
by centrifugation in hematocrit capillaries.
Cell Culture. Human umbilical vein endothelial cells (HUVECs)
were prepared as described previously (Kiemer et al., 2002a) and
cultured in endothelial cell growth medium (Provitro, Berlin, Ger-
many) containing 10% fetal bovine serum (Biochrom, Berlin, Ger-
many). Cells were used for experiments at passages 1 to 3.
Measurement of Transendothelial Electric Resistance
(TEER). HUVECs were cultured on collagen A (Biochrom)-coated
Millicell 12-mm PCF inserts (Millipore, Schwalbach, Germany).
TEER measurements were performed with an Ussing-type chamber.
The incubation fluid (HEPES-buffer containing 10% fetal bovine
serum) was circulated by means of humidified air streams at 37°C. A
custom-built voltage/current clamp unit in connection with a com-
puter-aided evaluation program was used. Bidirectional square cur-
rent pulses of 50 A and 200 ms duration were applied across the
monolayer every 2 s. The resistance of the monolayer was calculated
by Ohm’s law from the induced deflection of the transendothelial
voltage.
Immunocytochemistry/Histochemistry and Confocal Laser
Scanning Fluorescence Microscopy. HUVECs were cultured on
collagen-treated -Slides (ibidi, Martinsried, Germany). The NPR-A/B
antagonist HS-142-1 (Morishita et al., 1991) was kindly provided by Dr.
Y. Matsuda (Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan). cANP
was from Bachem (Weil am Rhein, Germany). HUVECs and samples of
the mouse cremaster muscle (immediately dissected after histamine
treatment) were analyzed immunocytochemically/histochemically and
by confocal fluorescence microscopy as described previously (Fu¨rst et
al., 2005). The following antibodies and reagents were used: mouse
monoclonal anti-VE-cadherin (Santa Cruz, Heidelberg, Germany), rab-
bit polyclonal anti-phospho-Tyr731-VE-cadherin (Biosource/Invitrogen,
Karlsruhe, Germany), rabbit polyclonal anti-phospho-MLC2 (Thr18/
Ser19; Cell Signaling/New England Biolabs, Frankfurt am Main, Ger-
many), rhodamine phalloidin (Invitrogen, Karlsruhe, Germany), Alexa
Fluor 633-linked goat anti-mouse (Invitrogen), and Alexa Fluor 488-
linked goat anti-rabbit (Invitrogen).
Western Blot Analysis. HUVECs were cultured in collagen-
treated six-well plates or 60-mm dishes. Western blot analysis was
performed as described previously (Kiemer et al., 2002a). The follow-
ing antibodies were used: rabbit polyclonal anti-phospho-Tyr731-
VE-cadherin (BioSource International, Camarillo, CA), mouse
monoclonal anti-VE-cadherin (Santa Cruz), rabbit polyclonal anit-
phospho-MLC2 (Thr18/Ser19) (Cell Signaling), and MLC2 (Santa
Cruz).
Statistical Analysis. Statistical analysis was performed with
Prism software (version 3.03; GraphPad Software, San Diego, CA).
Unpaired t test was used to compare two groups. To compare three or
more groups, one-way analysis of variance followed by Newman-
Keuls post hoc test was used.
Results
ANP Protection against an Inflammation-Impaired
Endothelial Barrier Function in Vivo. To judge endothe-
lial permeability in vivo, we measured the extravasation of
FITC-dextran (150 kDa) via intravital fluorescence micros-
copy in postcapillary venules of the mouse cremaster muscle.
Twenty minutes after intra-arterial application of ANP (bo-
lus sufficient to reach 200 nM plasma concentration), hista-
mine (30 M) was superfused for 10 min. Histamine evoked
a strong leak of FITC-dextran from the blood into the adja-
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Fig. 1. ANP attenuated histamine-induced increase of endothelial permeability in vivo and in vitro. A, extravasation of FITC-dextran (150 kDa) from
venules of the mouse cremaster muscle was measured. Top left, mice were pretreated with Ringer’s solution (control and histamine group) or with ANP
(intra-arterial bolus injection sufficient to reach 200 nM plasma concentration). After 20 min, histamine (30 M) was superfused for 10 min (histamine
and ANPhistamine group). Data are expressed as mean S.E.M. (n 6). , p 0.05 versus histamine. Top right, one representative image is shown
for each group of treatment (at time point 45 min for control, histamine, and histamine  ANP; at time point 30 min for ANP alone). Videos showing
this FITC-dextran extravasation (movie1, control; movie2, histamine; movie3, ANPhistamine) are available as supplemental data. Bottom left, mice
were treated with Ringer solution (control group) or with ANP (intra-arterial bolus injection sufficient to reach 200 nM plasma concentration). Data
are expressed as mean  S.E.M. (n  6). Bottom right, mice were pretreated with Ringer’s solution (histamine group) or with dexamethasone (10
mg/kg of body weight, i.p.) for 2 h. Histamine (30 M) was superfused for 10 min. Data are expressed as mean  S.E.M. (n  2). B, plasma volume
changes were determined by measuring hematocrit values. Rats were pretreated with PBS (control) or with ANP (i.v. bolus injection sufficient to reach
200 nM plasma concentration). After 15 min, histamine was applied (i.v. bolus injection sufficient to reach 1 M plasma concentration). 30 min later,
blood samples were taken and hematocrit was measured. Data are expressed as mean  S.E.M. (n  3). , p  0.05 versus histamine. C,
transendothelial electrical resistance (TEER) was used to judge changes in endothelial permeability of HUVECs. Left, histamine concentration-
dependently decreases TEER values. Middle, ANP (1 M, 30 min pretreatment) attenuates the histamine-induced decrease of electrical resistance.
One representative graph of four independent experiments is shown. Right, statistical analysis of all experiments performed (n  4). Data are
expressed as mean  S.E.M. , p  0.05 versus histamine.
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cent tissue. ANP clearly abrogated the histamine-induced
extravasation (Fig. 1A, top). Movies of this extravasation are
presented as supplemental data (movie1, control; movie2,
histamine; movie3, ANP histamine). ANP alone (at least in
the observed 20-min pretreatment) seemed to slightly in-
crease basal permeability (please note the different ordinate
scales in Fig. 1A), but this effect was statistically not signif-
icant (Fig. 1A, bottom left). Moreover, we aimed to appraise
the therapeutical impact of ANP by comparing its beneficial
effect with that of a strong anti-inflammatory drug. Thus, we
treated mice with a high dose of dexamethasone (10 mg/kg
i.p., 2 h) before applying histamine (30 M). The glucocorti-
coid completely prevented the histamine-induced extravasa-
tion of FITC-dextran.
As a second approach for detecting changes of endothelial
permeability in vivo, we measured hematocrit levels. Rats
were treated with histamine (i.v. bolus sufficient to reach 1
M plasma concentration), and hematocrit concentration
was determined after 30 min. Because of a reduction in
plasma volume (i.e., augmented fluid extravasation), hista-
mine evoked a strong hematocrit increase. ANP (bolus injec-
tion sufficient to reach 200 nM plasma concentration, 15-min
pretreatment) significantly reduced the permeability-in-
creasing effect of histamine (Fig. 1B).
Characterization of the Barrier-Protecting Effect of
ANP in Vitro.Data about an influence of ANP on histamine-
induced endothelial leakage in vitro are completely lacking.
Thus, we first aimed to verify the effect of ANP in HUVECs.
To judge permeability changes, TEER was measured. Upon
applying histamine, the electrical resistance of a HUVEC
monolayer rapidly dropped within seconds and recovered
after approximately 10 min. The extent of this effect is de-
pendent on the histamine concentration used: the resistance
was lowered to 55% by 10 M and to 85% by 1 M histamine
(Fig. 1C, left). ANP (1 M, 30 min pretreatment) attenuated
the drop-down of electrical resistance evoked by histamine
(Fig. 1C, middle). The statistical analysis of all experiments
(n  4) performed is depicted in Fig. 1C, right. The large
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Fig. 2. ANP inhibited the histamine-
evoked morphological changes of adhe-
rens junctions. HUVECs were left un-
treated (control) or were treated with
histamine (1 M, 2 min) alone or in
combination with ANP (1 M, 30 min
pretreatment) or the NPR-C agonist
cANF (1 M, 30 min pretreatment).
The NPR-A/B receptor antagonist HS-
142-1 (10 g/ml) was given 10 min be-
fore ANP. Immunocytochemistry and
confocal fluorescence microscopy were
performed to analyze morphological
changes of VE-cadherin (A), -catenin
(B), and p120ctn (C). One representa-
tive image of three independent exper-
iments is shown.
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variability of the ANP  histamine group expresses the fact
that in two of the four experiments, ANP not only attenuated
the effect of histamine but also increased the endothelial
resistance (i.e., led to a less permeable endothelium), even if
compared with the basal resistance under control conditions.
In summary, ANP strongly alleviated endothelial barrier
dysfunction induced by histamine in vitro. This warranted
the usage of this system for the following investigations into
the action of ANP on adherens junctions and the contractile
machinery.
ANP Effects on the Histamine-Evoked Changes of
Adherens Junction Morphology and the Histamine-
Induced VE-Cadherin Tyrosine Phosphorylation. His-
tamine (1 M) led to strong changes of AJ morphology: the
VE-cadherin, -catenin, and p120ctn seam, properly built in
untreated endothelial cells (control), becomes fringy, indicat-
ing an AJ disassembly (i.e., the retraction of the interendo-
thelial VE-cadherin homodimers and/or an intramembra-
nous lateral shift) (Fig. 2, A–C). Endothelial cells treated
with ANP alone showed no effect on AJs. Most importantly,
ANP (1 M, 30-min pretreatment) clearly abolished the det-
rimental effects induced by histamine (Fig. 2, A–C).
To clarify which natriuretic peptide receptor is involved in
mediating the beneficial actions of ANP, we treated cells with
the NPR-A/B antagonist HS-142-1 (10 g/ml, 10 min before
ANP) and found that the effects on VE-cadherin disassembly
were prevented by this inhibitor. The NPR-C receptor ago-
nist cANF (1 M, 30 min before histamine) was unable to
mimic the effects of ANP (Fig. 2A). Compared with NPR-B,
NPR-A binds ANP with a much higher affinity. Thus, our
results suggest that the action of ANP was mainly trans-
duced by NPR-A. The C-receptor seemed not to be involved.
Phosphorylation of the VE-cadherin Tyr731 residue is as-
sociated with AJ disassembly and strong endothelial leakage
in vitro (Potter et al., 2005). First, we verified that Tyr731 was
also phosphorylated by histamine in vivo: vessels of the
mouse cremaster muscle showed a strong increase of Tyr731
phosphorylation induced by histamine (30 M, 10 min; Fig.
3A) and the same pronounced localization at cell fringes (Fig.
3A, longitudinal vessel section) as in the in vitro situation
(Fig. 3B). Most importantly, as shown both by microscopic
(Fig. 3B) and by Western blot analysis (Fig. 3C), ANP com-
pletely blocked the histamine-induced VE-cadherin Tyr731
phosphorylation. ANP alone evoked no alterations of the
phosphorylation (Fig. 2B). Our data clearly point toward a
protecting effect of ANP on the integrity of endothelial adhe-
rens junctions.
ANP Effects on the Histamine-Evoked Activation of
MLC and the Formation of F-Actin Stress Fibers. The
generation of contractile forces (interaction of actin and my-
osin) is governed by MLC Thr18/Ser19-phosphorylation. His-
tamine treatment time-dependently led to a strong phosphor-
ylation of MLC, which was analyzed microscopically (Fig. 4A)
and by Western blotting (Fig. 4B). Moreover, histamine
evoked a strong change in F-actin organization. Although
quiescent endothelial cells showed a cortical F-actin localiza-
tion, histamine induced the formation of long, cell-spanning
stress fibers (Fig. 4C). ANP clearly reduced both MLC phos-
phorylation (Fig. 4, A and B) and F-actin stress fiber forma-
tion (Fig. 4C). ANP alone had no effect on these parameters
(Fig. 4, A-C). These results indicate that ANP prevented
histamine-evoked activation of the endothelial cell contrac-
tion system.
Furthermore, we investigated which NP receptor subtype
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Fig. 3. ANP blocked histamine-in-
duced VE-cadherin Tyr731-phosphory-
lation. A, histamine induces phos-
phorylation of VE-cadherin at Tyr731
in vivo. Mice were treated as described
in Fig. 1A. Samples of the mouse cre-
master muscle were analyzed via im-
munohistochemistry and confocal flu-
orescence microscopy. Histamine (30
M) was superfused for the indicated
times. One representative image of
three independent experiments is
shown. B and C, ANP inhibits hista-
mine-induced VE-cadherin Tyr731-phos-
phorylation in vitro. HUVECs were left
untreated (control) or were treated with
histamine (1 M, 5 min) or ANP (1 M,
30 min) alone or with ANP (1 M) 30
min before histamine was applied. The
VE-cadherin Tyr731-phosphorylation
was analyzed via immunocytochemistry
and confocal fluorescence microscopy
(B, n  3) or biochemically via Western
blot (C, n  2).
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was involved in mediating these effects. The NPR-A/B inhib-
itor HS-142-1 (10 g/ml, 10 min before ANP) blocked the
effects of ANP on MLC phosphorylation (Fig. 4A) and stress
fiber formation (Fig. 4C). The NPR-C agonist cANF (1 M, 30
min) was unable to show beneficial effects (Fig. 4, A and C).
Thus, NPR-A/B could be regarded as the major receptors for
transducing the actions of ANP in our setting.
Discussion
Many severe pathologic conditions, such as sepsis or ath-
erosclerosis, are associated with an inflammation-impaired
endothelial barrier function leading to an increased plasma
extravasation and thus edema formation (Volk and Kox,
2000; Poredos, 2001). Proinflammatory mediators, such as
TNF- or histamine, are involved in the pathogenesis of
these disorders and are strong inducers of vascular leakage.
Current therapies against an inflammation-evoked barrier
dysfunction (e.g., the administration of glucocorticoids or an-
tihistamines) are often insufficient or even fail (van Nieuw
Amerongen and van Hinsbergh, 2002). Therefore, new ther-
apeutical options are needed. Strong progress has been made
in recent years concerning the mechanisms involved in the
regulation of endothelial permeability (Mehta and Malik,
2006). However, substances that counteract an inflamma-
tion-induced vascular leakage by specifically influencing
these mechanisms are still largely lacking (van Nieuw Amer-
ongen and van Hinsbergh, 2002).
Initially, the physiological action of the cardiovascular hor-
mone ANP (i.e., the reduction of blood pressure) was mainly
ascribed to its natriuretic, diuretic, and vasodilating action.
However, ANP was also found to increase endothelial perme-
ability (Huxley et al., 1987). This effect was proven to be
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Fig. 4. ANP inhibited histamine-in-
duced MLC2 Thr18/Ser19-phosphoryla-
tion and stress fiber formation. A–C,
HUVECs were left untreated (control)
or were treated with histamine (1 M,
5 min) alone or in combination with
ANP (1 M, 30 min pretreatment) or
the NPR-C agonist cANF (1 M, 30
min pretreatment). The NPR-A/B re-
ceptor antagonist HS142-1 (10 g/ml)
was given 10 min before ANP. MLC2
Thr18/Ser19-phosphorylation and F-ac-
tin were analyzed via immunocyto-
chemistry and confocal fluorescence
microscopy (A and C). MLC2 Thr18/
Ser19-phosphorylation was addition-
ally analyzed via Western blot (B).
One representative image of at least
three independent experiments is
shown.
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crucial for the long-term control of plasma volume by ANP
(Sabrane et al., 2005). Beyond these permeability-increasing
effects on quiescent endothelial cells, ANP has increasingly
been recognized to possess barrier-protecting actions on an
inflammation-activated endothelium. We could demonstrate
that ANP attenuates the TNF--induced expression of adhe-
sion molecules and monocyte chemoattractant protein-1 by
inhibiting NF-B activation and p38 mitogen-activated pro-
tein kinase signaling (Kiemer et al., 2002b; Weber et al.,
2003). In this context, we showed that ANP protects against
TNF--evoked endothelial barrier dysfunction in HUVECs
(Kiemer et al., 2002a). ANP was also shown to lower endo-
thelial leakage in vitro induced by the pro-inflammatory
stimuli thrombin (Baron et al., 1989) and VEGF (Pedram et
al., 2002).
Thus, ANP has commonly been suggested to work as a
barrier-protecting agent. Surprisingly, an obvious question
remains unanswered precisely: can ANP be used as pharma-
cological agent to prevent endothelial barrier dysfunction in
vivo? This issue is of special interest, because the drug ANP
(carperitide) could open new therapeutical options for pro-
tecting endothelial barrier function. In the present study, we
for the first time show that ANP administered at a pharma-
cological concentration is able to prevent endothelial leakage
in a (histamine-induced) inflammatory setting in vivo. Dif-
ferent aspects of endothelial permeability were used as read-
out parameters and were all beneficially influenced by ANP:
macromolecular permeability (FITC-dextran extravasation),
plasma volume/fluid changes (hematocrit), and electrical re-
sistance (TEER measurement). Compared with the maximal
increase of FITC-dextran extravasation induced by hista-
mine (time point 45 min in Fig. 1A), ANP led to a reduction
of approximately 65%. Given this pronounced effect, a ther-
apeutical impact of ANP is not unlikely. A complete blockage
of the deleterious effect of histamine was observed in the
presence of an extraordinarily high dosage of the glucocorti-
coid dexamethasone, a highly potent anti-inflammatory
drug.
Former studies dealing with ANP and vascular permeabil-
ity served as valuable hints toward an in vivo relevance of
ANP as barrier-protecting agent. However, these reports did
not concisely test the hypothesis that administered ANP
exerts beneficial effects on endothelial barrier dysfunction in
vivo, because they either used ex vivo models or focused on
the endogenous ANP system. 1) Three older reports demon-
strate that pharmacological concentrations of ANP attenuate
changes of pulmonary wet weight induced by toxic agents,
such as reactive oxygen metabolites, paraquat, or arachi-
donic acid in ex vivo models of isolated-perfused lungs from
rabbits or guinea pigs (Inomata et al., 1987; Imamura et al.,
1988; Lofton et al., 1991). 2) Blockade of endogenous ANP
was shown to deteriorate pulmonary edema formation in rats
suffering from high-altitude–induced (Irwin et al., 2001) or
HCl-evoked (Wakabayashi et al., 1990) pulmonary vascular
leakage, whereas mice lacking the major ANP-degrading en-
zyme neutral endopeptidase were found to be less susceptible
for pulmonary leakage (Irwin et al., 2005a). It is noteworthy
that Pedram et al. (2002) showed that VEGF-induced vascu-
lar leakage is attenuated in ANP-overexpressing mice,
whereas these mice are not protected against histamine-
evoked leakage. This might be due to the much lower ANP
levels in these animals (plasma level: 40 pM) compared
with our setting, in which ANP is exogenously supplied to
reach a pharmacological plasma concentration of 200 nM.
Recently, our group could demonstrate that ANP-treated
mice (plasma level, 35 nM) are protected against LPS-
induced septic shock (Ladetzki-Baehs et al., 2007). Because
endothelial hyperpermeability is an important pathological
feature of sepsis, it can be speculated that the barrier-pro-
tecting effect of ANP contributes to the beneficial action in
the mouse septic shock model. Our results suggest that phar-
macological concentrations of ANP show additional, highly
valuable effects beyond its action as an endogenous regulator
of permeability.
Adherens junctions and the contractile apparatus are key
players in the regulation of endothelial permeability. Both
the loss of VE-cadherin function and the activation of MLC
result in decreased transendothelial electrical resistance
(Garcia et al., 1997; van Buul et al., 2005) and increased
macromolecular permeability (Garcia et al., 1995; Nwariaku
et al., 2002). Studies investigating the action of ANP on these
key systems are as yet completely lacking. We provide the
first evidence that ANP interacts with these systems, be-
cause we showed that ANP attenuated both adherens junc-
tion disassembly (morphological changes and Tyr731 phos-
phorylation of VE-cadherin) and activation of the contractile
apparatus (phosphorylation of MLC and rearrangement of
F-actin) induced by histamine. Furthermore, we could dem-
onstrate that ANP exerts these effects predominantly via
NPR-A. Because this receptor represents particulate guany-
late cyclases, it can be speculated that the actions of ANP
might be mediated via the second messenger cyclic GMP. Our
results add further support to the hypothesis that ANP is an
endothelium-protecting agent, because it directly counter-
acts the detrimental effects of proinflammatory mediators on
endothelial barrier function.
Few data exist regarding the action of ANP on subcellular
systems and its contribution to permeability regulation. We
and others could demonstrate that ANP inhibits F-actin
stress fiber formation induced by TNF- (Kiemer et al.,
2002a; Irwin et al., 2005b) or VEGF (Pedram et al., 2002).
Interestingly, one study reports that ANP influences tight
junctions in bovine aortic endothelial cells (Pedram et al.,
2002). In contrast to the dense aortic endothelium, the occur-
rence of tight junctions is limited in the venous endothelium
(Ogunrinade et al., 2002), which represents the predominant
site of endothelial hyperpermeability and was investigated in
the present study.
In summary, we have revealed ANP as a potent endothelial
barrier-protecting agent in vivo. Moreover, we have identi-
fied adherens junctions and the contractile apparatus as
important subcellular systems targeted by ANP. Most impor-
tantly, our study highlights ANP as an interesting pharma-
cological compound opening a new therapeutic option for the
prevention of vascular leakage. This warrants further efforts
aiming for an expansion of the therapeutic indications of
natriuretic peptides.
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